Impact of COVID-19 on Alpha-1 Antitrypsin Deficiency Treatment Market landscape, Forecast to 2025

Market Forecast

The Global Alpha-1 Antitrypsin Deficiency Treatment Market is expected to cross USD 2,914.7 Million by 2025 at a CAGR of 10.50%.Growing product pipeline for alpha-1 antitrypsin drugs and rising prevalence of alpha-1 antitrypsin deficiency are set to drive the market growth for alpha-1 antitrypsin deficiency treatment. Approximately 100,000 people in the US are known to suffer from alpha-1 antitrypsin deficiency.Rising awareness regarding the alpha-1 antitrypsin deficiency is expected to drive the growth of the global alpha-1 antitrypsin deficiency treatment market.Strategic mergers & acquisitions are also projected to boost market growth with companies looking to strengthen their market positions, expand their product portfolios, and improve their brand images.

Download Sample of This Strategic Report- https://www.kennethresearch.com/sample-request-10159195

For instance, on 3rd September 2019, Kamada Pharmaceuticals signed an agreement with Takeda Pharmaceutical Ltd for supply and distribution of Glassia, which is an alpha-1 proteinase inhibitor used for the treatment of alpha-1 antitrypsin deficiency.High unmet medical needs in developing economies are directly providing lucrative opportunities for the market growth.

Market Influencers

The rising number of product approvals. For instance, in September 2017, Grifols S.A. received a biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C.

Market Drivers

Increasing prevalence of alpha-1 antitrypsin deficiency. Alpha-1 antitrypsin deficiency or AATD is a genetic disease that may cause severe lung or liver disfunction. The prevalence of alpha-1 antitrypsin deficiency is increasing, which is resulting in market growth. 1 in 1500 to 3500 Europeans are affected by AATD. Since the prevalence of AATD is increasing, the demand for treatment of AATD is also increasing, which is resulting in the positive growth of the alpha-1 antitrypsin deficiency treatment market.Growing product pipeline for alpha-1 antitrypsin deficiency treatment drugs

By Drugs

Alpha-1 Proteinase Inhibitor: This drug type is expected to hold the largest market share. In April 2019, CSL Behring received FDA approval for Zemaira, which is alpha-1 proteinase inhibitor. So, the rising number of product approvals is expected to drive the market growth.

Download Sample of This Strategic Report- https://www.kennethresearch.com/sample-request-10159195

Bronchodilators: Used for prevention from upper respiratory tract infections.Steroids: Consists of corticosteroids used for the treatment of COPD associated with AATD.Others: Consists of oxygen therapy, antibiotics, and other drugs used for the treatment of complications associated with AATD, such as jaundiced skin, breathing problems, etc.

By Route of Administration

Oral: This route of administration is expected to hold the largest market share due to its high usage.Intravenous: This drug type is expected to grow at the fastest rate owing to the ease of administration.Inhalation: This route of administration is mainly used for administration of corticosteroids and drugs for the treatment of breathing disorders associated with AATD.

Others: Consists of subcutaneous and intramuscular routes of administration.

By Distribution Channel

Hospital Pharmacy: The segment holds the largest market size as the treatment is mostly carried out in hospitals.Retail Pharmacy: They provide prescriptions that are intended to be used at home.Online Stores: Fastest growing segment owing to the increasing number of online pharmacy stores.

By Region

Americas: The largest regional market. The high patient population suffering from alpha-1 antitrypsin deficiency is expected to drive the market growth. Approximately 1 in 2,500 Americans suffer from the disease. This serves to drive the growth of the alpha-1 antitrypsin deficiency treatment market in the region.Europe: Europe has some of the best healthcare services in the world. Increasing prevalence and the developed healthcare industry are driving the market growth.

Request For Full Report- https://www.kennethresearch.com/sample-request-10159195

Asia-Pacific: The fastest-growing regional market for alpha-1 antitrypsin deficiency treatment, Asia-Pacific has the world’s largest population and fast-developing healthcare industry which is anticipated to drive the market growth.Middle East & Africa: The market growth is attributed to the developing healthcare industry in regions such as Saudi Arabia, Oman, and Qatar.

Key Players

Kamada Pharmaceuticals (Israel): Offers Glassia, an alpha-1 antitrypsin deficiency treatment drug. It also has inhalation AATD drug in Phase 2 clinical trials in the US and phase 3 clinical trials in Europe.CSL Behring LLC (US): Leading provider of plasma-derived and recombinant therapeutic products for rare diseases such as AATD. Hosted the symposium about AATD treatment in Paris.

Grifols, S.A. (Spain): Offers the Grifols Prolastin -C Liquid (alpha-1 proteinase inhibitor) for the treatment of AATD since 2017.Takeda Pharmaceutical Company Limited (Japan): Manufactures drugs for emphysema which is a main form of AATD.GlaxoSmithKline plc (UK): The company offers bronchodilators for the treatment of AATD.Boehringer Ingelheim GmbH (Germany): Manufacturer and distributor for bronchodilators.

Request For Full Report- https://www.kennethresearch.com/sample-request-10159195

AstraZeneca (UK): Offers bronchodilators such as the Bevespi Aerosphere inhalation aerosol for treatment of COPD associated with AATD.

Vectura Group plc (UK): Offers Ultibro Breezhaler dual bronchodilator.

Pfizer Inc. (US): Offers the Spiriva Handihaler bronchodilator for the treatment of COPD associated with AATD.

Mylan Inc. (US): Received FDA approval in November 2018 for YUPELRI, a long-acting muscarinic antagonist nebulized bronchodilator.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products’ demand, growth and opportunities for new and existing players.

Contact Us

Kenneth Research
Email: Sales@kennethresearch.com
Phone: +1 313 462 0609

James Bullock is a Research Expert with a demonstrated history of working in the professional training & coaching industry. Strong professional skilled in business strategy , Strategic Planning, Research Strategy, and Marketing. also have interest in new innovations and technology

Leave a Reply